🇺🇸 FDA
Patent

US 10080730

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

granted A61KA61K31/557A61K31/5585

Quick answer

US patent 10080730 (Treatment of vasculopathy with prostacyclin and mesenchymal stem cells) held by United Therapeutics Corporation expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/557, A61K31/5585, A61K35/28, A61P